

Title	Borna disease virus possesses an NF- $\kappa$ B inhibitory sequence in the nucleoprotein gene.
Author(s)	Makino, Akiko; Fujino, Kan; Parrish, Nicholas F; Honda, Tomoyuki; Tomonaga, Keizo
Citation	Scientific reports (2015), 5
Issue Date	2015-03-03
URL	<a href="http://hdl.handle.net/2433/196633">http://hdl.handle.net/2433/196633</a>
Right	This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a>
Type	Journal Article
Textversion	publisher



## OPEN

# Borna disease virus possesses an NF- $\kappa$ B inhibitory sequence in the nucleoprotein gene

## SUBJECT AREAS:

INNATE IMMUNITY

VIRAL IMMUNE EVASION

VIRUS-HOST INTERACTIONS

Akiko Makino<sup>1,2</sup>, Kan Fujino<sup>1\*</sup>, Nicholas F. Parrish<sup>1</sup>, Tomoyuki Honda<sup>1,3</sup> & Keizo Tomonaga<sup>1,3,4</sup>Received  
10 October 2014Accepted  
2 February 2015Published  
3 March 2015

Correspondence and requests for materials should be addressed to A.M. (akkmakino@gmail.com) or K.T. (tomonaga@virus.kyoto-u.ac.jp)

\* Current address:  
Department of Microbiology II, School of Veterinary Medicine, Azabu University, Fuchinobe, Chuo-ku, Sagamiharashi, Kanagawa, 252-5201, Japan

<sup>1</sup>Department of Viral Oncology, Kyoto University, Kyoto 606-8507, Japan, <sup>2</sup>Center for Emerging Virus Research, Institute for Virus Research, Kyoto University, Kyoto 606-8507, Japan, <sup>3</sup>Department of Tumor Viruses, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan, <sup>4</sup>Department of Mammalian Regulatory Network, Graduate School of Biostudies, Kyoto University, Kyoto 606-8507, Japan.

Borna disease virus (BDV) has a non-segmented, negative-stranded RNA genome and causes persistent infection in many animal species. Previous study has shown that the activation of the I $\kappa$ B kinase (IKK)/NF- $\kappa$ B pathway is reduced by BDV infection even in cells expressing constitutively active mutant IKK. This result suggests that BDV directly interferes with the IKK/NF- $\kappa$ B pathway. To elucidate the mechanism for the inhibition of NF- $\kappa$ B activation by BDV infection, we evaluated the cross-talk between BDV infection and the NF- $\kappa$ B pathway. Using Multiple EM for Motif Elicitation analysis, we found that the nucleoproteins of BDV (BDV-N) and NF- $\kappa$ B1 share a common ankyrin-like motif. When THP1-CD14 cells were pre-treated with the identified peptide, NF- $\kappa$ B activation by Toll-like receptor ligands was suppressed. The 20S proteasome assay showed that BDV-N and BDV-N-derived peptide inhibited the processing of NF- $\kappa$ B1 p105 into p50. Furthermore, immunoprecipitation assays showed that BDV-N interacted with NF- $\kappa$ B1 but not with NF- $\kappa$ B2, which shares no common motif with BDV-N. These results suggest BDV-N inhibits NF- $\kappa$ B1 processing by the 20S proteasome through its ankyrin-like peptide sequence, resulting in the suppression of IKK/NF- $\kappa$ B pathway activation. This inhibitory effect of BDV on the induction of the host innate immunity might provide benefits against persistent BDV infection.

**B**orna disease virus belongs to the order *Mononegavirales* and possesses a non-segmented, negative-stranded RNA genome. The characteristic properties of this virus include its broad host range in vertebrates<sup>1-3</sup> and its ability to establish persistent infection in the cell nucleus<sup>4-6</sup>. The BDV genome encodes 6 genes in the following 3' to 5' order: nucleoprotein (N), phosphoprotein (P), X, matrix protein (M), glycoprotein (G), and polymerase protein (L)<sup>7-9</sup>. The M protein undercoats the viral envelope<sup>10,11</sup>, and the G protein mediates viral entry into host cells<sup>12-14</sup>. The N, P, and L proteins form the polymerase complex and perform roles in the transcription and replication of the viral genome<sup>15-17</sup>.

Most likely due to the 3' to 5' transcription initiation gradient<sup>8</sup>, the N protein is the most abundant viral proteins in acutely infected cells<sup>18</sup> and animals<sup>19</sup>; it is also the dominant target of the humoral<sup>20</sup> and CD8<sup>+</sup>-T-cell-mediated immune reactions<sup>21</sup>. In most infected cells, the N protein is concentrated in viral replication factories in the nucleus<sup>22</sup>; however, it is capable of nucleocytoplasmic shuttling due to a nuclear export signal as well as a nuclear localization signal<sup>23</sup>. These properties make N a strong candidate for a viral gene that influences host cell functions, including innate immunity.

When a cell is infected with a virus, pattern recognition receptors (PRRs) rapidly sense non-self nucleic acids and proteins, leading to the activation of the antiviral innate immune response<sup>24</sup>. One key downstream component of this response, type I interferon, has been shown to inhibit BDV infection in a number of experimental systems<sup>25,26</sup>. Given the wide range of cells in which BDV effectively establishes persistent infection, it is unsurprising that it has evolved many strategies to avoid triggering PRRs as well as to interrupt their signaling cascades. BDV modifies the termini of its RNA genome in a way that avoids recognition by the cytoplasmic innate receptor RIG-I<sup>27,28</sup>. In addition, BDV can inhibit MAVS, a molecule important for activating transcription factors, including IRF3 and 7, after PRR engagement<sup>29</sup>. Finally, BDV inhibits TBK-1, a kinase needed to phosphorylate IRF3 and 7, which allows them to enter the nucleus to transcribe interferon and other innate immune effectors<sup>30</sup>. Thus, BDV avoids or counteracts the innate immune response at multiple levels. Innate immune pathways are often redundant and partially overlapping; thus, BDV may utilize additional unknown mechanisms to thor-



oughly antagonize the host response. For example, BDV is inhibited by the constitutive activation of NF- $\kappa$ B<sup>31</sup>, but no BDV proteins that interact with this molecule have been identified.

NF- $\kappa$ B is a transcription factor involved in immune induction, embryonic development, and cell proliferation in response to various extracellular stimuli<sup>32,33</sup>. The NF- $\kappa$ B family consists of five genes, NF- $\kappa$ B1, NF- $\kappa$ B2, RelA, RelB, and c-Rel, which form homo- or heterodimers in the cytoplasm<sup>34,35</sup>. When the NF- $\kappa$ B signaling pathway is activated, I $\kappa$ B, which is an inhibitory factor of NF- $\kappa$ B, is phosphorylated by I $\kappa$ B kinase (IKK) and degraded by the 20S proteasome<sup>36</sup>. This process frees NF- $\kappa$ B to translocate into the nucleus, where it behaves as a transcription factor<sup>32,33</sup>. When cells expressing constitutively active IKK are stimulated with tetradecanoyl phorbol acetate, a potent NF- $\kappa$ B signaling pathway stimulus, NF- $\kappa$ B activation is lower in BDV-infected cells than in mock cells. This difference suggests that BDV infection suppresses the IKK/NF- $\kappa$ B signaling pathway downstream of IKK<sup>31</sup>.


To better understand how BDV evades innate immunity and establishes persistent infection, we first confirmed that BDV suppresses NF- $\kappa$ B activation, then aimed to determine the mechanism by which it does so. It has previously been reported that certain cell-penetrating peptides with sequence motifs in common with specific NF- $\kappa$ B family genes can competitively inhibit the NF- $\kappa$ B signaling pathway<sup>37–39</sup>. Furthermore, a viral peptide derived from the vaccinia virus A46 protein (VIPER) inhibits the Toll-like receptor 4 (TLR4) signaling pathway, which also mediates signal transduction using NF- $\kappa$ B by binding to the BB loop of Toll/interleukin-1 receptor (TIR) domains of the receptor and adaptor, thus disrupting the receptor-adaptor interaction<sup>40,41</sup>. We thus searched the BDV proteins for motifs shared with the NF- $\kappa$ B family proteins, aiming to identify NF- $\kappa$ B

inhibitory peptide sequences to elucidate the mechanism by which BDV suppresses NF- $\kappa$ B activation.

Here, we show that BDV-N shares a common ankyrin-like motif with NF- $\kappa$ B1. In cells, this BDV-N-derived peptide inhibits the NF- $\kappa$ B signaling pathway. The inhibitory peptide derived from BDV-N demonstrates another mechanism used by BDV to overcome innate immunity and establish persistent infection.

## Results

**BDV infection inhibits NF- $\kappa$ B activation.** To first assess the reproducibility of the previous data that BDV suppresses the processing and activation of NF- $\kappa$ B during infection<sup>31</sup>, we employed THP1-CD14 cells<sup>42</sup>. These cells express secreted alkaline phosphatase (SEAP) under the control of a promoter that is activated by NF- $\kappa$ B. THP1-CD14 cells were infected with rBDV P/M-GFP<sup>43</sup>, and the resulting SEAP activity was measured at from 12 h to 2 weeks post-infection. The SEAP activity in the culture supernatant was not significantly elevated above the level from mock-infected cells at any point over the 2 weeks (Figure 1A), suggesting a lack of detectable NF- $\kappa$ B activation induced by BDV infection in THP1-CD14 cells. In contrast, the addition of the positive control, the TLR1/2 agonist Pam3CSK4, at a 100 ng/ml concentration for 24 hours led to readily detectable SEAP production. These data could indicate that BDV avoids recognition by PRRs that signal through NF- $\kappa$ B or, alternatively, that BDV may be recognized by such PRRs but their signaling is interrupted prior to the activation of NF- $\kappa$ B. To distinguish between these alternatives, we attempted to activate NF- $\kappa$ B in persistently BDV-infected cells using Pam3CSK4. BDV-infected cells secreted less SEAP than mock cells when activated with Pam3CSK4 (Figure 1B), suggesting that BDV-infected cells actively suppress NF- $\kappa$ B signaling. To assess whether



**Figure 1 | BDV infection suppresses NF- $\kappa$ B activation.** (A) THP1-CD14 cells were infected with cell-free rBDV P/M-GFP at a multiplicity of infection of 0.1, and the resulting supernatants were collected. The SEAP activity was determined at the indicated time points (N = 3). (B) THP1-CD14 cells infected with rBDV P/M-GFP were stimulated with 100 ng/ml of TLR1/2 ligand (Pam3CSK4). At 48 h post-stimulation, GFP-positive cells were measured using an image-based cytometer. Error bars represent standard deviation of the mean (N = 3). \*\*:  $P = 0.00474$  (one-tailed t-test) (C) THP1-CD14 cells infected with rBDV P/M-GFP were stimulated with 100 ng/ml of TLR1/2 ligand (Pam3CSK4). The SEAP activities of the supernatants were determined at 24 h post-stimulation. Error bars represent the standard deviation of the mean (N = 3). \*\*:  $P = 0.00761$  (one-tailed t-test)



NF- $\kappa$ B activation has a deleterious effect on viral replication, we activated NF- $\kappa$ B using Pam3CSK4 in cultures of THP1-CD14 cells that had been exposed to BDV 7 days earlier. Forty-eight hours after stimulation, we measured the extent of infection by determining the percentage of GFP-expressing cells. NF- $\kappa$ B activation with Pam3CSK4 resulted in significantly fewer BDV-infected cells in the culture (Figure 1C). These data are consistent with a previous report<sup>31</sup> and indicate that BDV infection inhibits NF- $\kappa$ B activation, which could otherwise impair BDV replication.

**Inhibition of NF- $\kappa$ B activation by a peptide derived from BDV-N.** Based on previous reports that peptides possessing common sequence motifs with specific NF- $\kappa$ B family genes competitively inhibit NF- $\kappa$ B signaling<sup>37–39</sup> and that VIPER derived from vaccinia virus A46 protein inhibits TLR4 signaling<sup>40,41</sup>, we screened for common motifs between BDV genes and the human NF- $\kappa$ B family to identify possible mechanisms underlying the observed inhibition of NF- $\kappa$ B activation in BDV-infected cells. For this purpose, we used Multiple EM for Motif Elicitation (MEME) analysis, a tool for the discovery of common motifs across amino acids sequences that uses the MM algorithm<sup>44,45</sup>. We detected several shared motifs (Table 1). We focused on a motif shared between BDV-N and NF- $\kappa$ B1 because both the length of the motif sequence (16 amino acids) and the localization of the motif (ankyrin repeat domain of NF- $\kappa$ B1<sup>32,33</sup>; exposed domain of BDV-N tetramer and monomer<sup>46</sup>) suggested that it could have a biologically relevant effect (Figure 2A and B).

To assess the inhibitory effect of the identified motif in BDV-N on NF- $\kappa$ B activation, THP1-CD14 cells were incubated with 100  $\mu$ g/ml of the viral peptide fused with a cell-penetrating peptide (nine arginine residues) at the C-terminus for 4 h. We then stimulated the cells with five different TLR ligands known to activate NF- $\kappa$ B, predicting that a direct interaction of the BDV-N peptide with NF- $\kappa$ B would block SEAP production regardless of the upstream pathway involved. Indeed, 24 h after stimulation with TLR ligands, NF- $\kappa$ B activation by all ligands was significantly suppressed in cells pre-treated with virus peptides derived from BDV-N ( $P = 0.00168$  for TLR1/2;  $P = 0.01198$  for TLR4;  $P = 0.00090$  for TLR2/6;  $P = 0.00862$  for TLR2;  $P = 0.01337$  for TLR7/8), as well as with the positive control VIPER ( $P = 0.00084$  for TLR1/2;  $P = 0.00823$  for TLR4;  $P = 0.00131$  for TLR2/6;  $P = 0.00203$  for TLR2;  $P = 0.00646$  for TLR7/8) (Figure 2C). In contrast, NF- $\kappa$ B signaling was highly activated by all TLR agonists in cells pre-treated with the control peptide CP7. These data suggest that the identified viral peptide inhibits NF- $\kappa$ B activation. We therefore refer to this peptide as the Inhibitory Peptide derived from BDV-N (IPBN).

**BDV-N and the peptide derived from BDV-N reduce NF- $\kappa$ B1 processing by the 20S proteasome.** The ankyrin repeat domain of NF- $\kappa$ B1 represses its transcription activity. Upon NF- $\kappa$ B pathway activation, NF- $\kappa$ B1 is phosphorylated, which promotes the processing of the ankyrin repeat-containing C-terminal region by the 20S proteasome and produces a shift in the molecular weight from 105 to 50<sup>36</sup>. We hypothesized that IPBN, and perhaps also intact BDV-N,

could inhibit NF- $\kappa$ B signaling by preventing this processing. To determine whether IPBN affects the processing of NF- $\kappa$ B1 p105 into p50, we performed an *in vitro* 20S proteasome assay using IPBN and affinity-purified recombinant BDV-N and NF- $\kappa$ B1 proteins, as previously reported<sup>36</sup>. As shown in Figure 3, when NF- $\kappa$ B1 was incubated with the control peptide and then with the 20S proteasome, p105 was markedly reduced, confirming NF- $\kappa$ B1 processing by the 20S proteasome. This processing could be effectively blocked using a protease inhibitor cocktail. Recombinant BDV-N and IPBN suppressed the processing of p105 as efficiently as the protease inhibitor ( $P = 0.03401$  for BDV-N;  $P = 0.03904$  for IPBN;  $P = 0.04556$  for protease inhibitor) (Figure 3A and B). These data suggest that BDV-N and IPBN inhibit NF- $\kappa$ B activation by preventing NF- $\kappa$ B1 processing by the 20S proteasome, allowing unprocessed NF- $\kappa$ B1 to act as I $\kappa$ B<sup>37,38</sup>, the inhibitory factor of NF- $\kappa$ B.

**The IPBN sequence is dispensable for the interaction of BDV-N with NF- $\kappa$ B1.** We focused our investigation on the BDV-N gene, as it contains a peptide with similarity to the ankyrin repeat domain of NF- $\kappa$ B. This peptide alone is capable of inhibiting NF- $\kappa$ B signaling; however, intact BDV-N protein also inhibits the processing of NF- $\kappa$ B1. Therefore, we determined whether intact BDV-N interacts with NF- $\kappa$ B1 using an immunoprecipitation assay. Lysates from cells expressing HA-tagged BDV-N and FLAG-tagged NF- $\kappa$ B1 or FLAG-tagged NF- $\kappa$ B2 were mixed for 30 min at 4°C, and the mixed cell lysates were immunoprecipitated with an anti-FLAG antibody (SIGMA). As shown in Figure 4A, BDV-N was co-immunoprecipitated with NF- $\kappa$ B1, but not with NF- $\kappa$ B2, which shares no common motif with BDV-N. This result indicates that BDV-N interacts specifically with NF- $\kappa$ B1. Interestingly, we found that alanine substitution or deletion of the IPBN amino acid sequence in BDV-N had no effect on co-immunoprecipitation with NF- $\kappa$ B1 (Figure 4B). Note that the increased binding property of L8A mutant to NF- $\kappa$ B1 might be resulted from its loose tetramer formation by the alanine replacement. In fact, the L8A mutant has four amino acid changes in the residues involved in the oligomerization of BDV-N, while F8A contains only one change<sup>46</sup>. Thus, the identified motif sequence is dispensable for the interaction of BDV-N with NF- $\kappa$ B1, suggesting that BDV-N interacts with NF- $\kappa$ B1 via additional domains not apparent at the level of motif similarity.


## Discussion

The ankyrin repeat domain of NF- $\kappa$ B1 binds to its Rel homology region, which leads to the repression of transcription factor activity (Figure 2A). The phosphorylation of NF- $\kappa$ B1 (p105) by signal transduction pathways induces the processing of its ankyrin repeat domain by the 20S and 26S proteasomes, and the mature p50 form gains transcription factor activity<sup>36,47</sup>. This study revealed that BDV has an ankyrin-like motif in common with NF- $\kappa$ B1 in its N gene. This peptide and intact BDV-N inhibit the processing of NF- $\kappa$ B1 from p105 to p50 by the 20S proteasome, suppressing NF- $\kappa$ B activation. At present, it is unclear exactly how BDV-N suppresses NF- $\kappa$ B1 processing by the 20S proteasome. However, we observed a direct

Table 1 | Extracted motifs

NF- $\kappa$ B Family	BDV gene	Motif sequence
NF- $\kappa$ B1	N	BDV-N <sup>187</sup> MFNPH <sup>EAIDWINGQ</sup> PW <sup>202</sup> NF- $\kappa$ B1 <sup>779</sup> MATSWQVFDILNGKPY <sup>794</sup>
NF- $\kappa$ B2	P	BDV-P <sup>145</sup> MKTMM <sup>ETM</sup> <sup>162</sup> NF- $\kappa$ B2 <sup>143</sup> KKNMM <sup>GTM</sup> <sup>160</sup>
RelA	Not extracted	
RelB	N	BDV-N <sup>186</sup> QMFNPH <sup>191</sup> RelB <sup>556</sup> NMFPNH <sup>561</sup>
c-Rel	G	BDV-G <sup>115</sup> DPFECNWFYCC <sup>125</sup> c-Rel <sup>560</sup> DAFEGSDFSCA <sup>571</sup>






**Figure 2 | Inhibitory effect of the virus peptide on NF-κB activation.** (A) Schematic diagram of NF-κB1 and BDV-N. (B) The crystallographic structure of the BDV-N tetramer and monomer (Protein Databank # 1N93). Yellow lines indicate the IPBN. (C) Inhibitory effect of the viral peptide on NF-κB activation. THP1-CD14 cells were pre-treated with 100 μg/ml of the viral peptide derived from BDV-N, a negative control peptide (CP7), or the positive control peptide (VIPER) and stimulated with five TLR ligands. At 24 h post-stimulation, the SEAP activities in the supernatants were measured. Error bars represent the standard deviation of the mean (N = 3).


interaction between BDV-N and NF-κB1. Furthermore, BDV-N itself was not degraded by the 20S proteasome, suggesting that it does not act as a decoy for NF-κB1 processing. The IPBN sequence was not necessarily required for the interaction between BDV-N and NF-κB1 (Figure 4B), indicating that at least one other domain within N is necessary to mediate this interaction. Together, our data suggest that the close proximity of BDV-N to NF-κB1 might be important for the efficient inhibitory effects of BDV-N on NF-κB activation. Our working hypothesis is that docking BDV-N onto NF-κB1 might mimic a longer ankyrin repeat domain, which has been reported to exert a suppressive effect on NF-κB1 processing<sup>47</sup>. Structural analysis shows that the ankyrin-like motif is exposed in the BDV-N tetramer and monomer<sup>46</sup>, consistent with this hypothesis (Figure 2B). However, our report has several limitations. At first, we couldn't detect the mature p50 from in the 20S proteasome assay, because of the failure to purify the recombinant NF-κB1 protein tagged at N-terminus, in addition to the low reactivity of the anti-p50 antibodies. We were also unable to test whether BDV-N interacts with NF-κB in infected cells and to rescue recombinant BDV, which has no IPBN. Furthermore, because the interaction of BDV-N with NF-κB1 is not strictly dependent on the identified peptide, we are still exploring strategies to disrupt this interaction while maintaining other critical virological functions of N, which would allow us to definitively assess the relevance of this interaction to BDV infection and persistence. We are now trying to rescue serial mutants of BDV via alanine substitution in IPBN. Further investigation is needed to elucidate the detailed mechanism of the inhibitory effect of BDV-N and IPBN on NF-κB1.

We successfully identified the shared motif between BDV-N and NF-κB1 using MEME analysis, which is a web server for discovering common motif(s) in DNA or protein sequences through the MM algorithm, an extension of the expectation maximization technique<sup>44,45</sup>. The identified motif was found to be well-conserved in both the BDV and avian bornavirus nucleoproteins. In 202 of the sequences available in GenBank at the time of submission, only two conservative changes (M187V and G199A) were present at higher than 15%. Indeed, the peptide generated from the identified motif efficiently suppressed NF-κB activation, indicating that MEME analysis is a useful tool in the search for antagonized motifs of viral protein to host genes. In addition to IPBN, we also found that the V protein of the Measles virus shares a motif with the TIR domains of the TIR-domain-containing adapter-inducing interferon-β (TRIF)-related adaptor molecule (TRAM) and myeloid differentiation primary-response gene 88 (MyD88)-adaptor-like (MAL), which are the adaptor proteins in the TLR signaling pathway<sup>48</sup>. The identified virus peptide (DRWCNPMC), which fused with the cell-penetrating peptide at the C-terminus, showed inhibitory effects on some of the TLR signaling pathways (Figure S1;  $P = 0.00105$  for TLR1/2;  $P = 0.10236$  for TLR4;  $P = 0.00475$  for TLR2/6;  $P = 0.00111$  for TLR2;  $P = 0.00596$  for TLR7/8). These data also strongly support the usefulness of this strategy.

Another interesting finding of this study is that the VIPER peptide that we chose as a positive control inhibited NF-κB signaling through all TLR agonists examined, as it has previously been reported to be specific for the TLR4 pathway<sup>40,41</sup>. However, we



**Figure 3** | The 20S proteasome assay. (A) NF- $\kappa$ B1 protein and BDV-N protein, the virus peptide derived from BDV-N or 1 X complete protease inhibitor cocktail, were incubated with 20S proteasome at 37°C for 1 h. To detect the p105 form of NF- $\kappa$ B1, SDS-PAGE and western blotting with anti-FLAG M2 monoclonal antibody were performed. BDV-N was detected using an anti-HA monoclonal antibody. Full-length blots are presented in Supplementary Figure 2. (B) The intensities of the p105 bands were quantified by ImageJ. The relative amount of the output p105 compared with the input p105 was calculated. The error bars represent the standard deviation of the mean (N = 3).



**Figure 4** | Interaction of BDV-N with NF- $\kappa$ B1. (A) Lysates from cells expressing HA-tagged BDV-N were mixed with lysates from cells transfected with FLAG-tagged NF- $\kappa$ B1 or FLAG-tagged NF- $\kappa$ B2 for 30 min at 4°C. Mixed cell lysates were then immunoprecipitated with an anti-FLAG M2 monoclonal antibody using Protein G Dynabeads. SDS-PAGE and western blotting with an anti-HA monoclonal antibody and anti-FLAG M2 monoclonal antibody were performed. Full-length blots are presented in Supplementary Figure 3. (B) Lysates from cells expressing HA-tagged BDV-N or HA-tagged IPBN-alanine substitution in the first 8 (F8A) or last 8 (L8A) amino acids or -deletion mutants ( $\Delta$ motif) of BDV-N were mixed with lysates from cells and transfected with the FLAG-tagged NF- $\kappa$ B1 for 30 min at 4°C. The mixed cell lysates were then subjected to an IP assay with anti-FLAG M2 monoclonal antibody using Protein G Dynabeads. Full-length blots are presented in Supplementary Figure 4.



believe that our results are valid and suggest a previously unrecognized breadth of VIPER inhibition. As shown in Figure 2, a control peptide did not inhibit signaling by any of the agonists tested. The identified peptide from the V protein of the Measles virus did not inhibit NF- $\kappa$ B signaling by the TLR4 agonist and had approximately half the inhibitory effect of either IPBN or VIPER on the other pathways (Figure S1). Together with the control peptide data, this result argues against a systemic bias toward pan-inhibition in our experimental system.

BDV antagonizes host innate immune functions in many ways: the genomic RNA of BDV escapes RIG-I recognition through the processing of the 5' terminus<sup>27,49</sup>; BDV-P counteracts Traf family member associated NF- $\kappa$ B activator-binding kinase 1 (TBK-1)-dependent IFN- $\beta$  expression by acting as a competitive inhibitor of TBK-1<sup>30</sup>; and BDV-X inhibits mitochondrial antiviral signaling protein-induced apoptosis<sup>29</sup>. By showing for the first time that BDV interacts with and inhibits NF- $\kappa$ B, a transcription factor used by many innate immune pathways to transduce signals into the nucleus, this study provides a key insight into how BDV might establish its characteristic persistent infection in the cell nucleus.

In summary, we have identified a viral peptide that shares motifs with and inhibits NF- $\kappa$ B, validating the use of the MEME tool for this purpose. This peptide and other peptides identified in this way could prove useful as pharmacological agents. IPBN inhibits NF- $\kappa$ B, which is being explored as a therapy for many diseases, such as cancer, asthma, and muscular dystrophy<sup>32,50</sup>. Furthermore, this result provides a starting point for dissecting virus/host protein interactions. Future studies of BDV-N/NF- $\kappa$ B interaction are warranted to better understand the strategies used by bornaviruses, which have been infecting vertebrate hosts for millions of years<sup>51</sup>, to counter innate immunity.

## Methods

**Cells, virus, and peptides.** THP1-CD14 cells (InvivoGen, San Diego, CA, USA) were maintained in Roswell Park Memorial Institute 1640 medium (SIGMA-ALDRICH Japan, Tokyo, Japan) with 10% fetal calf serum (FCS), 1X Penicillin-Streptomycin Solution (Wako, Osaka, Japan), 200  $\mu$ g/ml of Zeocin<sup>TM</sup> (Life Technologies Japan, Tokyo, Japan), 250  $\mu$ g/ml of G418 (InvivoGen), and 100  $\mu$ g/ml of Normocin (InvivoGen). The 293T cells and BDV-infected Vero cells were grown in Dulbecco's modified Eagle's minimal essential medium (Life Technologies Japan) with 10% FCS and 1X Penicillin-Streptomycin Solution.

The virus used in this study was recombinant BDV, which expresses GFP inserted between the P and M genes of BDV strain He/80, named rBDV P/M-GFP<sup>43,52</sup>. To prepare cell-free rBDV P/M-GFP, Vero cells persistently infected with rBDV P/M-GFP were sonicated (BioRuptor UCD-300) and centrifuged at 1200  $\times$  g for 25 min at 4°C. The supernatant was collected and used as cell-free rBDV P/M-GFP.

The virus-derived peptide (MFNPHEAIDWINGQPW), control peptide (RNTISGNIYSA), and VIPER (KYSFKLILAEY) with cell-penetrating peptide (nine arginine residues) at the C-terminus were custom synthesized (Life Technologies Japan).

**MEME analysis.** Amino acid sequences of all BDV genes were submitted to the MEME web server (<http://meme.nbcr.net/meme/cgi-bin/meme.cgi>) along with one gene from each of the five human NF- $\kappa$ B families. The motif search criteria were set as follows: the width of the motif ranged from 6 to 50 AA, with a maximum of 3 motifs per gene and a maximum of 2 sites per motif.

**NF- $\kappa$ B activation assay.** THP1-CD14 cells express TLRs and CD14 at high levels and express the SEAP gene in a NF- $\kappa$ B-dependent manner. To assess the SEAP production, the culture supernatant of THP1-CD14 cells was incubated with QUANTI-Blue<sup>TM</sup> (InvivoGen) for 1 h at 37°C, after which the optical density (OD) at 650 nm was measured using a Microplate reader SH-9000 (CORONA ELECTRIC Co., Ltd). To assess the NF- $\kappa$ B activation by BDV infection, THP1-CD14 cells were infected with cell-free rBDV P/M-GFP at a multiplicity of infection of 0.1, and the supernatant was harvested and SEAP measured at 12 h, 1 d, 2 d, 3 d, and 2 weeks post-infection. To evaluate the effect of NF- $\kappa$ B activation on BDV infection, a culture of THP1-CD14 cells approximately 30% infected with rBDV P/M-GFP was stimulated with 100 ng/ml of the TLR1/2 ligand. GFP-positive cells were measured using a Tali<sup>®</sup> Image Cytometer (Life Technologies Japan) at 48 h post-stimulation, and the SEAP activity was assessed at 24 h post-stimulation.

To evaluate the inhibitory effects of the virus peptide on NF- $\kappa$ B activation, 2  $\times$  10<sup>5</sup> THP1-CD14 cells were incubated with 100  $\mu$ g/ml of each peptide for 4 h at 37°C, then subjected to stimulation with 100 ng/ml of Pam3CSK4, 10 ng/ml of TLR4 ligand (LPS), 10 ng/ml of TLR 2/6 ligand (FSL-1), 10<sup>7</sup> cells/ml of TLR2 ligand (heat killed *L.*

*Monocytogenes*), and 5  $\mu$ g/ml of TLR 7/8 ligand (CL075) (all from InvivoGen), respectively. At 24 h after stimulation, the SEAP activity of the supernatant was determined as described above. The results shown represent the means of three independent experiments. The P values were calculated using a one-tailed t-test.

**The 20S proteasome assay.** We performed the 20S proteasome assay as previously described<sup>46</sup>. Briefly, BDV-N and NF- $\kappa$ B1 proteins were purified with antibodies using Dynabeads Protein G (Life Technologies Japan). The NF- $\kappa$ B1 protein and BDV-N protein, IPBN, or 1 X complete protease inhibitor cocktail (Roche Diagnostic K.K., Tokyo, Japan) were incubated with the 20S proteasome (Boston Biochem, Cambridge, MA, USA) at a molecular ratio of 25:25:1 in a buffer solution (20 mM Tris pH 7.0, 250 mM NaCl, 10 mM MgCl<sub>2</sub>, and 1 mM DTT) at 37°C for 1 h. The resultant proteins were subjected to SDS-PAGE and western blotting with an anti-FLAG M2 monoclonal antibody (SIGMA-ALDRICH Japan) to detect the p105 form of NF- $\kappa$ B1. The p50 form was not detected because of the cleavage of the C-terminal FLAG during 20S processing. BDV-N was detected using an anti-HA monoclonal antibody.

**Immunoprecipitation (IP) assay.** For the IP assay, 293T cells were transfected with pcDNA3 encoding BDV-N, alanine substitution mutants in the first 8 (F8A) or last 8 (L8A) amino acids of IPBN, or IPBN deletion mutants of BDV-N tagged with HA at N-terminus, pCMV6 expressing NF- $\kappa$ B1 fused with FLAG-tag at C-terminus (OriGene Technologies, Inc., Rockville, MD, USA), and pCMV6 expressing NF- $\kappa$ B2 fused with FLAG-tag at C-terminus (OriGene Technologies, Inc.), and the cells were then lysed in a buffer containing 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton-X, 1 mM EDTA, and 1 X complete protease inhibitor cocktail. Cell lysate expressing HA-tagged BDV-N or BDV-N mutants was mixed with cell lysate transfected with FLAG-tagged NF- $\kappa$ B1 or FLAG-tagged NF- $\kappa$ B2 for 30 min at 4°C, and the mixed cell lysates were immunoprecipitated with anti-FLAG M2 monoclonal antibody using Protein G Dynabeads, according to the manufacturer's instructions. The mixed cell lysates and IP products were subjected to SDS-PAGE and western blotting using an anti-HA monoclonal antibody (Abcam, Cambridge, UK) and an anti-FLAG M2 monoclonal antibody.

- Rott, R. & Becht, H. Natural and experimental Borna disease in animals. *Curr Top Microbiol Immunol* **190**, 17–30; DOI: 10.1007/978-3-642-78618-1\_2 (1995).
- Kinnunen, P. M., Palva, A., Vaheri, A. & Vapalahti, O. Epidemiology and host spectrum of Borna disease virus infections. *J Gen Virol* **94**, 247–262; DOI:10.1099/vir.0.046961-0 (2013).
- Staeli, P., Sauder, C., Hausmann, J., Ehrensperger, F. & Schwemmler, M. Epidemiology of Borna disease virus. *J Gen Virol* **81**, 2123–2135; DOI:10.1099/vir.0.17095-0 (2000).
- Tomonaga, K., Kobayashi, T. & Ikuta, K. Molecular and cellular biology of Borna disease virus infection. *Microbes Infect* **4**, 491–500; DOI:10.1016/S1286-4579(02)01564-2 (2002).
- De la Torre, J. C. Bornavirus and the brain. *J Infect Dis* **186 Suppl.**, S241–247; DOI:10.1086/344936 (2002).
- Hornig, M., Briesse, T. & Lipkin, W. I. Borna disease virus. *J Neurovirol* **9**, 259–273; DOI: 10.1080/13550280390194064 (2003).
- Briesse, T., de la Torre, J. C., Lewis, A., Ludwig, H. & Lipkin, W. I. Borna disease virus, a negative-strand RNA virus, transcribes in the nucleus of infected cells. *Proc Natl Acad Sci U S A* **89**, 11486–11489; DOI: 10.1073/pnas.89.23.11486 (1992).
- Briesse, T. *et al.* Genomic organization of Borna disease virus. *Proc Natl Acad Sci U S A* **91**, 4362–4366; DOI: 10.1073/pnas.91.10.4362 (1994).
- Schneider, U. Novel insights into the regulation of the viral polymerase complex of neurotropic Borna disease virus. *Virus Res* **111**, 148–160; DOI:10.1016/j.virusres.2005.04.006 (2005).
- Neumann, P. *et al.* Crystal structure of the Borna disease virus matrix protein (BDV-M) reveals ssRNA binding properties. *Proc Natl Acad Sci U S A* **106**, 3710–3715; DOI: 10.1073/pnas.0808101106 (2009).
- Kraus, I. N. A. *et al.* Open Reading Frame III of Borna Disease Virus Encodes a Nonglycosylated Matrix Protein. *J Virol* **75**, 12098–12104; DOI: 10.1128/JVI.75.24.12098 (2001).
- Bajramovic, J. J. *et al.* Borna Disease Virus Glycoprotein Is Required for Viral Dissemination in Neurons. *J Virol* **77**, 12222–12231; DOI: 10.1128/JVI.77.22.12222 (2003).
- Gonzalez-dunia, D., Cubitt, B., Gra, F. A., Carlos, J. & Torre, D. E. L. A. Characterization of Borna disease virus p56 protein, a surface glycoprotein involved in virus entry. *J Virol* **71**, 3208–3218; DOI: 0022-538X/97/04.0010 (1997).
- Perez, M., Watanabe, M., Whitt, M. A., Torre, C. De & Perez, M. A. R. N-Terminal Domain of Borna Disease Virus G (p56) Protein Is Sufficient for Virus Receptor Recognition and Cell Entry. *J Virol* **75**, 7078–7085; DOI: 10.1128/JVI.75.15.7078 (2001).
- Martin, A., Staeli, P. & Schneider, U. RNA polymerase II-controlled expression of antigenomic RNA enhances the rescue efficacies of two different members of the Mononegavirales independently of the site of viral genome replication. *J Virol* **80**, 5708–5715; DOI: 10.1128/JVI.02389-05 (2006).
- Perez, M. A reverse genetics system for Borna disease virus. *J Gen Virol* **84**, 3099–3104; DOI: 10.1099/vir.0.19467-0 (2003).



17. Ackermann, A., Staeheli, P. & Schneider, U. Adaptation of Borna disease virus to new host species attributed to altered regulation of viral polymerase activity. *J Virol* **81**, 7933–7940; DOI: 10.1128/JVI.00334-07 (2007).
18. Watanabe, M. *et al.* Molecular ratio between borna disease viral-p40 and -p24 proteins in infected cells determined by quantitative antigen capture ELISA. *Microbiol Immunol* **44**, 765–772; DOI: 10.1111/j.1348-0421.2000.tb02561.x (2000).
19. Haas, B., Becht, H. & Rott, R. Purification and properties of an intranuclear virus-specific antigen from tissue infected with Borna disease virus. *J Gen Virol* **67** (Pt2), 235–241; DOI: 10.1099/0022-1317-67-2-235 (1986).
20. Briese, T., Hatalski, C. G., Kliche, S., Park, Y. & Lipkin, W. I. Enzyme-linked immunosorbent assay for detecting antibodies to Borna disease virus-specific proteins. *J Clin Microbiol* **33**, 348–351; DOI: 0095-1137/95/\$04.0010 (1995).
21. Planz, O. & Stitz, L. Borna disease virus nucleoprotein (p40) is a major target for CD8(+) T-cell-mediated immune response. *J Virol* **73**, 1715–1718; DOI:0022-538X/99/\$04.0010 (1999).
22. Matsumoto, Y. *et al.* Bornavirus closely associates and segregates with host chromosomes to ensure persistent intranuclear infection. *Cell Host Microbe* **11**, 492–503; DOI: 10.1016/j.chom.2012.04.009 (2012).
23. Kobayashi, T., Kamitani, W. & Zhang, G. Borna disease virus nucleoprotein requires both nuclear localization and export activities for viral nucleocytoplasmic shuttling. *J Virol* **75**, 3404–3412; DOI:10.1128/JVI.75.7.3404 (2001).
24. Kawai, T. & Akira, S. Innate immune recognition of viral infection. *Nat. Immunol.* **7**, 131–137; DOI: 10.1038/ni1303 (2006).
25. Von Rheinbaben, F., Stitz, L. & Rott, R. Influence of interferon on persistent infection caused by Borna disease virus in vitro. *J Gen Virol* **66**, 2777–2780; DOI:10.1099/0022-1317-66-12-2777 (1985).
26. Hallensleben, W., Staeheli, P. & Virologie, A. Inhibition of Borna disease virus multiplication by interferon: cell line differences in susceptibility. *Arch Virol* **144**, 1209–1216; DOI: 10.1007/s007050050580 (1999).
27. Habjan, M. *et al.* Processing of genome 5' termini as a strategy of negative-strand RNA viruses to avoid RIG-I-dependent interferon induction. *PLoS One* **3**, e2032; DOI: 10.1371/journal.pone.002032 (2008).
28. Schneider, U., Martin, A., Schwemmler, M. & Staeheli, P. Genome trimming by Borna disease viruses: viral replication control or escape from cellular surveillance? *Cell Mol Life Sci* **64**, 1038–1042; DOI: 10.1007/s00018-007-6545-9 (2007).
29. Li, Y. *et al.* MAVS-mediated host cell defense is inhibited by Borna disease virus. *Int J Biochem Cell Biol* **45**, 1546–1555; DOI: 10.1016/j.biocel.2013.05.012 (2013).
30. Unterstab, G. *et al.* Viral targeting of the interferon- $\beta$ -inducing Traf family member-associated NF- $\kappa$ B activator (TANK)-binding kinase-1. *Proc Natl Acad Sci U S A* **102**, 13640–13645; DOI: 10.1073/pnas.0502883102 (2005).
31. Bourteele, S. *et al.* Constitutive activation of the transcription factor NF- $\kappa$ B results in impaired borna disease virus replication. *J Virol* **79**, 6043–6051; DOI:10.1128/JVI.79.10.6043-6051.2005 (2005).
32. Hayden, M. S. & Ghosh, S. Shared principles in NF- $\kappa$ B signaling. *Cell* **132**, 344–362; DOI: 10.1016/j.cell.2008.01.020 (2008).
33. Sen, R. & Baltimore, D. Inducibility of K Immunoglobulin Enhancer-Binding Protein NFKB by a Posttranslational Mechanism. *Cell* **47**, 921–926; DOI:10.1016/0092-8674(86)90807-X (1985).
34. Manuscript, A. Molecular basis of NF- $\kappa$ B signaling. *Annu Rev Biophys* **42**, 443–468; DOI: 10.1146/annurev-biophys-083012-130338 (2013).
35. Ghosh, S., Karin, M. & Haven, N. Missing pieces in the NF- $\kappa$ B puzzle. *Cell* **109**, 81–96; DOI: 10.1016/S0092-8674(02)00703-1 (2002).
36. Moorthy, A. K. *et al.* The 20S proteasome processes NF- $\kappa$ B p105 into p50 in a translation-independent manner. *EMBO J* **25**, 1945–1956; DOI:10.1038/sj.emboj.7601081 (2006).
37. Fujihara, S. *et al.* Inhibition of NF- $\kappa$ B by a cell permeable form of I  $\kappa$ B  $\alpha$  induces apoptosis in eosinophils. *Biochem Biophys Res Commun* **326**, 632–637; DOI: 10.1016/j.bbrc.2004.11.090 (2005).
38. Lin, Y. Z., Yao, S. Y., Veach, R. A., Torgerson, T. R. & Hawiger, J. Inhibition of nuclear translocation of transcription factor NF- $\kappa$ B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. *J Biol Chem* **270**, 14255–14258; DOI: 10.1074/jbc.270.24.14255 (1995).
39. Kabouridis, P. S., Hasan, M., Newson, J., Gilroy, D. W. & Lawrence, T. Inhibition of NF- $\kappa$ B activity by a membrane-transducing mutant of I  $\kappa$ B  $\alpha$ . *J Immunol* **169**, 2587–2593; DOI: 10.4049/jimmunol.169.5.2587 (2002).
40. Stack, J. & Bowie, A. G. Poxviral protein A46 antagonizes Toll-like receptor 4 signaling by targeting BB loop motifs in Toll-IL-1 receptor adaptor proteins to disrupt receptor:adaptor interactions. *J Biol Chem* **287**, 22672–22682; DOI: 10.1074/jbc.M112.349225 (2012).
41. Lysakova-Devine, T. *et al.* Viral inhibitory peptide of TLR4, a peptide derived from vaccinia protein A46, specifically inhibits TLR4 by directly targeting MyD88 adaptor-like and TRIF-related adaptor molecule. *J Immunol* **185**, 4261–4271; DOI: 10.4049/jimmunol.1002013 (2010).
42. Chanput, W., Mes, J. J. & Wichers, H. J. THP-1 cell line: An in vitro cell model for immune modulation approach. *Int Immunopharmacol* **23**, 37–45; DOI:10.1016/j.intimp.2014.08.002 (2014).
43. Daito, T. *et al.* A novel borna disease virus vector system that stably expresses foreign proteins from an intercistronic noncoding region. *J Virol* **85**, 12170–12178; DOI: 10.1128/JVI.05554-11 (2011).
44. Bailey, T. L. *et al.* MEME SUITE: tools for motif discovery and searching. *Nucleic Acids Res* **37**, W202–208; DOI: 10.1093/nar/gkp335 (2009).
45. Bailey, T. L. & Elkan, C. Fitting a mixture model by expectation maximization to discover motifs in biopolymers. *Proc. Int. Conf. Intell. Syst. Mol. Biol.* **2**, 28–36; DOI: 10.1093/nar/gkp335 (1994).
46. Rudolph, M. *et al.* Crystal Structure of the Borna Disease Virus Nucleoprotein. *Structure* **11**, 1219–1226; DOI: 10.1016/j.str.2003.08.011 (2003).
47. Cohen, S., Orian, A. & Ciechanover, A. Processing of p105 is inhibited by docking of p50 active subunits to the ankyrin repeat domain, and inhibition is alleviated by signaling via the carboxyl-terminal phosphorylation/ubiquitin-ligase binding domain. *J Biol Chem* **276**, 26769–26776; DOI: 10.1074/jbc.M102448200 (2001).
48. O'Neill, L. A. J. & Bowie, A. G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. *Nat. Rev. Immunol.* **7**, 353–364; DOI: 10.1038/nri2079 (2007).
49. Martin, A., Hoefs, N., Staeheli, P. & Schneider, U. Genomic RNAs of Borna disease virus are elongated on internal template motifs after realignment of the 3' termini. *Proc Natl Acad Sci U S A* **108**, 7206–7211; DOI: 10.1073/pnas.1016759108 (2011).
50. Ruland, J. Return to homeostasis: downregulation of NF- $\kappa$ B responses. *Nat. Immunol.* **12**, 709–714; DOI: 10.1038/ni.2055 (2011).
51. Horie, M. *et al.* Endogenous non-retroviral RNA virus elements in mammalian genomes. *Nature* **463**, 84–87; DOI: 10.1038/nature08695 (2011).
52. Thierer, J. *et al.* The 24 K protein of Borna disease virus. *J Gen Virol* **73**, 413–416; DOI: 10.1099/0022-1317-73-2-413 (1992).

## Acknowledgments

This study was supported in part by the Funding Program for Next Generation World-Leading Researchers (NEXT program), Grants-in-Aid for Scientific Research (26253027 and 26670225) and the Core-to-Core Program A, Advanced Research Networks from the Japan Society for the Promotion of Science (JSPS) (KT), grants from Takeda Science Foundation (KT), a Grant-in-Aid for Research Fellowship of JSPS for Young Scientists (25860336) (TH), and a Grant-in-Aid for Scientific Research on Innovative Areas (25115508) (TH) from the Ministry of Education, Culture, Sports and Technology (MEXT) of Japan.

## Author contributions

A.M. designed the study, conducted the experiments, performed the majority of the data analysis, and wrote the manuscript with supervision from K.T., K.F. provided the new reagents; K.F. and T.H. analyzed the data; A.M., N.F.P. and K.T. wrote the paper.

## Additional information

**Supplementary information** accompanies this paper at <http://www.nature.com/scientificreports>

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Makino, A., Fujino, K., Parrish, N.F., Honda, T. & Tomonaga, K. Borna disease virus possesses an NF- $\kappa$ B inhibitory sequence in the nucleoprotein gene. *Sci. Rep.* **5**, 8696; DOI:10.1038/srep08696 (2015).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>